Finance

Beta
Lists
OCS:NASDAQ
Oculis Holding AG
$12.00
+2.21%
(+0.26) 1D
$11.75
-2.08% (-0.25)
Pre-market
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OCS...
Open
$11.69
High
$12.01
Low
$11.57
Mkt. cap
744.50M
Avg. vol.
1.02M
Volume
252.00
52-wk high
$34.48
52-wk low
$10.52
EPS
-$2.12
Beta
0.12
Shares outstanding
67.79M
No. of employees
60
Open
$11.69
High
$12.01
Low
$11.57
Mkt. cap
744.50M
Avg. vol.
1.02M
Volume
252.00
52-wk high
$34.48
52-wk low
$10.52
EPS
-$2.12
Beta
0.12
Shares outstanding
67.79M
No. of employees
60
News stories
From sources across the web
About Oculis Holding AG
CEO-
Employees60
Founded2017
HeadquartersZug, Zug, Switzerland
SectorPharmaceutical industry
Websiteoculis.com
Analyst ratings
Based on 10 analysts giving stock ratings to OCS in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for OCS in the last 3 months.
Highest
Current $12.00
$53.00 (+341.67%)
Average
$38.30 (+219.17%)
Lowest
$23.00 (+91.67%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yi Chen
H.C. Wainwright
Buy
Reiterated
$26.00
+116.7%
06/11/2026
Patrick Dolezal
LifeSci Capital
Buy
Maintained
$45.00
+275%
06/06/2026
Tessa Romero
J.P. Morgan
Buy
Maintained
$23.00
+91.7%
06/03/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$40.00
+233.3%
06/02/2026
Colleen M. Kusy
Robert W. Baird
Buy
Maintained
$38.00
+216.7%
06/01/2026
Jason Gerberry
Bank of America Securities
Buy
Maintained
$35.00
+191.7%
06/01/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$45.00
+275%
06/01/2026
Serge Belanger
Needham
Buy
Maintained
$38.00
+216.7%
06/01/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
$40.00
+233.3%
06/01/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
$53.00
+341.7%
05/12/2026
Previous reportsAll values in CHF
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CHF
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
261.00K
243.00K
411.00K
209.00K
Cost of goods sold
14.91M
14.12M
13.29M
14.05M
Cost of revenue
14.91M
14.12M
13.29M
14.05M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.12M
6.42M
7.76M
7.89M
Operating expense
6.12M
6.42M
7.76M
7.89M
Total operating expenses
21.03M
20.54M
21.04M
21.94M
Operating income
-20.77M
-20.30M
-20.63M
-21.73M
Other non operating income
-234.00K
3.09M
-3.24M
-7.98M
EBT including unusual items
-25.40M
-16.84M
-23.70M
-28.95M
EBT excluding unusual items
-25.40M
-16.84M
-23.70M
-28.95M
Income tax expense
-24.00K
13.00K
-182.00K
-98.00K
Effective tax rate
0.09%
-0.08%
0.77%
0.34%
Other operating expenses
-
-
-
-
Net income
-25.38M
-16.86M
-23.51M
-28.85M
Net profit margin
-9,722.22%
-6,936.21%
-5,721.17%
-13,804.78%
Earnings per share
-0.49
-0.32
-0.42
-0.49
Interest and investment income
520.00K
438.00K
319.00K
367.00K
Interest expense
-183.00K
-162.00K
-241.00K
-173.00K
Net interest expenses
337.00K
276.00K
78.00K
194.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.66M
-20.14M
-20.60M
-21.57M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of OCS
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer